Clarissa Parker to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Clarissa Parker has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.089
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
Score: 0.058
-
A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15.
Score: 0.031